Latest Biotech News

Cerevance said its Phase 3 trial of oral solengepras met its primary endpoint by reducing Parkinson’s patients’ daily “off” time in people experiencing motor fluctuations despite levodopa. The...

Matchpoint Therapeutics, a Novartis-partnered company, raised $150 million in a Series B to advance its lead program into human testing. The financing underscores how corporate partnerships are...

Caribou Biosciences said it is shutting down after failing to secure sufficient capital to fund a late-stage clinical trial of its off-the-shelf CAR-T therapy for lymphoma. The company announced...

A healthcare AI readiness and governance-focused session emphasized that deployment risk is not just a model problem—it requires ongoing vigilance across implementation and oversight. Drawing on...

A new perspective highlighted “context engineering” as the system-level discipline needed to build reliable AI systems, reframing prompt engineering as only one subset of the broader problem. The...

A global coalition committed $1.8 billion to build open data infrastructure for training AI models of biology. The group includes Biohub, the U.S. Department of Energy, NIH, Google DeepMind,...

Researchers introduced a privacy-preserving hybrid federated learning framework to detect deepfakes without sharing sensitive datasets. The approach, FedHybrid-ViT, combines convolutional and...

A large real-world study found that GLP-1 receptor agonists are associated with sharply lower cardiovascular risks in obese patients with obstructive sleep apnea. Researchers reported reduced...

AbbVie and Genmab reported Phase 3 success for Epkinly in newly diagnosed diffuse large B-cell lymphoma, cutting the risk of disease progression or death by nearly half versus chemotherapy alone....

Forbion collected €2.3 billion across two new venture funds, described as its largest-ever fundraising haul. The investor said the capital will support roughly 30 companies, positioning the new...

Genentech struck a $1.27 billion deal with Alector to bring AL050, a preclinical enzyme replacement therapy targeting GCase deficiency, into its hands for global development. Genentech paid $100...

Caribou Biosciences said it is exploring strategic alternatives and will discontinue its two donor-derived allogeneic CAR-T programs, including vispa-cel for relapsed or refractory B-cell...

AbbVie and Genmab reported Phase 3 success for Epkinly (Glofitamab) in first-line diffuse large B-cell lymphoma, reducing the risk of disease progression or death by nearly half versus...

Shionogi agreed to acquire IntraBio for $2 billion, aiming to expand its rare-disease portfolio with an asset marketed for Niemann-Pick disease type C and positioned for further label growth....

The FTC sent warning letters to 24 healthcare organizations over alleged shortcomings in prescription price transparency. The enforcement step focuses on how organizations present pricing...

A study of a Chinese wastewater treatment plant found that advanced treatment steps can backfire by increasing anti-androgenic activity above a newly derived risk threshold, even as other...

A multicenter study reported an MRI-radiomics and machine-learning approach that predicts lymphovascular invasion and stratifies gastric cancer patients by disease-free survival risk before...

Real-world data continued to support immunotherapy expansion in HER2-low metastatic breast cancer, with a cohort showing trastuzumab deruxtecan delivering a median progression-free survival of 9.1...

RougeTx raised $58 million in a Series A to advance an oral small-molecule therapy candidate for hereditary hemorrhagic telangiectasia (HHT). The company’s approach centers on reattaching...

A translational study reported early feasibility for non-invasive temporal interference stimulation aimed at a deep thalamic arousal target. In mice, the approach reportedly promoted wakefulness,...